Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433765 · ClinicalTrials.gov registry record
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 728
- Enrollment target
- 1
- Study location
NCT06433765: Recruiting study of Multiple Sclerosis, sponsored by TG Therapeutics.
NCT06433765 is a study of Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 728 participants, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (25% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06433765, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 728 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
North Carolina
- BRIUMVI® Pregnancy Registry Virtual Research Coordination Center - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2035-03-31 |
What NCT06433765 shows while recruiting
NCT06433765 is an observational study that tracks outcomes without assigning an intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT06433765 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06433765 about?
NCT06433765 is a clinical study titled "A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)". The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
What is the current status of trial NCT06433765?
This trial is currently recruiting. The enrollment target is 728 participants. The study started on 2024-06-01. Estimated completion is 2035-03-31.
What conditions does trial NCT06433765 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06433765?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT06433765?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433765 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06433765's enrollment target sits among peer trials
728 37th of 315 higher than 279 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI